Your session is about to expire
← Back to Search
HZN-825 for Scleroderma
Study Summary
This trial will measure the safety and efficacy of a drug given to people with systemic sclerosis over a year.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I can follow the trial's requirements and have no health issues that could interfere.I agree to use effective birth control during and for 4 weeks after the trial.I was diagnosed with a new cancer after joining Trial HZNP-HZN-825-301, except for skin or early cervical cancer which were treated successfully.
- Group 1: HZN-825
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there still opportunities for participants to join this experiment?
"That is accurate. According to information on clinicaltrials.gov, this medical trial which was initially published on November 4th 2022, continues seeking participants actively. 300 people need to be recruited at 1 centre for the study's completion."
Has the FDA granted clearance to HZN-825?
"Our team has assessed HZN-825's safety to be a 2, as there is some documentation confirming the medication's security but no clinical evidence of its efficacy."
How many individuals have opted to take part in this experiment?
"Affirmative. Clinicaltrials.gov displays that this clinical trial is presently seeking participants, with the initial posting occurring on November 4th 2022 and an update made on November 15th 2022. 300 individuals must be enrolled from 1 site in total."
Share this study with friends
Copy Link
Messenger